Breathe Well Live Well
|
Ajanta Pharma gets USFDA nod for generic asthma treatment drug
Economic Times NEW DELHI: Drug firm Ajanta Pharma has received final approvals from the US health regulator for generic montelukast tablets and oral granules used for prevention and treatment of asthma and to relieve symptoms of seasonal hay fever. The company has … |
View full post on asthma – Google News
Medgadget.com (blog) |
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
|
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class …
PR Newswire (press release) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
|
Research and Markets: Frontier Pharma: Asthma – Identifying and …
Business Wire (press release) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
|
Positive results for Sanofi/Regeneron's dupilumab in asthma
The Pharma Letter French pharma major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) have released positive results from the interim analysis of a dose-ranging Phase IIb study of dupilumab in adult patients with uncontrolled … |
View full post on asthma – Google News
The Pharma Letter |
Asthma market to remain stable over next decade, despite generic erosion
The Pharma Letter New market potential in underserved asthma population: Emerging anticytokines that are predicted to launch during the next decade will serve part of the unmet need in the severe, refractory asthma population, which is currently served by only systemic … |
View full post on asthma – Google News
|
Asthma's treatment pipeline very strong as more personalized medicines emerge
The Pharma Letter According to research and consulting firm GlobalData's latest report, the most significant challenge in asthma therapeutics is posed by patients with severe forms of the disease, who remain uncontrolled and have frequent exacerbations, even with the … |
View full post on asthma – Google News
|
Apellis Pharma raises $17.6M; focuses on asthma and COPD
MedCity News But the company's site says it is approaching chronic inflammatory diseases like asthma and chronic obstructive pulmonary disease by modifying them rather than suppressing systems. Waiting on a call back from COO Pascal Deschatelets to discuss the … |
View full post on asthma – Google News
The Pharma Letter |
Global asthma market to hit $18 billion by 2021 boosted by biologics
The Pharma Letter Natasha Spiller, an analyst at Datamonitor Healthcare said: “Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated, despite the use of inhaled corticosteroids and long-acting beta 2 … |
View full post on asthma – Google News
The Pharma Letter |
GSK and Theravance submit US sNDA for Breo Ellipta in asthma
The Pharma Letter Today's filing is based on data generated from the comprehensive clinical development program for FF/VI in asthma. The clinical development program comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients … Glaxo, Theravance File Asthma Drug Application with FDA Glaxo submits new drug application for asthma treatment GSK and Theravance Announce Submission to US Regulatory Authorities for … |
View full post on asthma – Google News